Genetic Engineering & Biotechnology News recently ran a brief article entitled “EU Sanctions Merck & Co.’s Sublingual Bipolar Disorder Drug Sycrest.” Sycrest was first approved in the U.S. in 2009 where Merck markets it as Saphris. Sycrest/Saphris is a “sublingual asenapine drug for treating moderate to severe manic episodes in adult patients with bipolar I disorder” and for treating schizophrenia. When used in treating bipolar disorder mania, it is most effective when used with other anti-manic medications, including lithium and Depakote.

Saphris/asenapine is the newest member of the class of drugs called atypical antipsychotics. It works in the same general manner – affecting primarily dopamine receptors. It also carries the same potential risks that we describe in our initial post on atypical antipsychotics. It is approved for use in schizophrenia and Bipolar I disorder for acute mania. It comes in a sublingual form (under the tongue), which some patients prefer, but which many people don’t like.

I have only had the opportunity to try it in one patient and she experienced severe sedation and stopped it. It was otherwise well tolerated. My thoughts at this point are that because this is a new medicine, with unknown safety profile in longer term use, it is probably going to be used primarily in individuals who have not responded to anything else for their condition.

The primary reason for using Saphris instead of one of the other atypical antipsychotics would be if Saphris were less prone than the others to cause weight gain. Unfortunately, Saphris has not proven much better than other atypical antipsychotics at avoiding this bothersome side effect.

 


Comments


View Comments / Leave a Comment

This post currently has 9 comments.
You can read the comments or leave your own thoughts.

Trackbacks

No trackbacks yet to this post.






    Last reviewed: 9 Sep 2010

APA Reference
Fink, C. (2010). Bipolar Disorder Medication Spotlight: Saphris. Psych Central. Retrieved on November 1, 2014, from http://blogs.psychcentral.com/bipolar/2010/09/bipolar-disorder-medication-spotlight-saphris/

 

Bipolar Beat


Subscribe to this Blog:
Feed

Bipolar
Disorder



Archives





Candida Fink, M.D. and Joe Kraynak are authors of
Bipolar Disorder for Dummies.


Best of the Web - Blog 2008

Subscribe to this Blog: Feed

Recent Comments
  • Sally: My daughter has lived in this involuntary nightmare for a year and 1/2. She had her first semester in college...
  • Tergiversada: Started on 5 mg. Abilify a little more than 3 years ago. It pulled me out of the blackest, most...
  • Emma 311: Also self-harms is a KEY feature of BPD along with having one of the highest suicide rates much more so...
  • Emma 311: You are very mislead about BPD, everything you mentioned so called “lacking in BPD” are very...
  • T: what’s best is to ask HER! its an illness not a retardation… just dont ask her while she is in an...
Find a Therapist
Enter ZIP or postal code



Users Online: 12240
Join Us Now!